贝伐珠单抗联合化疗方案治疗非小细胞肺癌的临床研究

Clinical Study of Bevacizumab Combined with Chemotherapy Regimen in the Treatment of Non-Small Cell Lung Cancer

目的 探讨贝伐珠单抗联合化疗方案治疗非小细胞肺癌(NSCLC)患者的临床效果。方法 选取2018年6月至2022年6月我院收治的66例NSCLC患者,随机分为常规组和联合组各33例。常规组采用化疗方案治疗,联合组采用贝伐珠单抗联合化疗方案治疗,比较两组患者的治疗效果、血清指标水平变化及生存质量。结果 联合组治疗总有效率为72.73%,高于常规组的48.48%(P <0.05)。治疗后,联合组血清CEA、 CA125、 CYFRA21-1水平均低于常规组(P <0.05)。治疗后,联合组肺癌患者生存质量测定量表(FACT-L)评分高于常规组(P <0.05)。结论 贝伐珠单抗联合化疗方案用于治疗NSCLC患者,可明显提升临床疗效,降低患者血清CEA、 CA125、 CYFRA21-1水平,提高其生存质量。

Objective To explore the clinical effect of bevacizumab combined with chemotherapy regimen in the treatment of non-small cell lung cancer(NSCLC).Methods 66 NSCLC patients admitted to our hospital from June 2018 to June 2022 were randomly divided into routine group and combined group,with 33 cases in each group.The routine group was treated with chemotherapy regimen,and the combined group was treated with bevacizumab combined with chemotherapy regimen.The treatment effect,serum indicator level and quality of life of the two groups were compared.Results The total effective rate of treatment in the combined group was 72.73%,higher than 48.48%in the routine group(P<0.05).After treatment,the serum CEA,CA125 and CYFRA21-1 levels of the combined group were lower than those in the routine group(P<0.05).After treatment,the FACT-L score of the combined group was higher than that of the routine group(P<0.05).Conclusions Bevacizumab combined with chemotherapy regimen in the treatment of NSCLC patients can significantly improve the clinical efficacy,reduce the serum CEA,CA125 and CYFRA21-1 levels,and improve the quality of life.